|
OUR STRENGTHS
- Vitreoretinal's products will address significant unmet needs in ophthalmic disease.
- VRT's products will be well positioned to serve the fast-growing specialty pharmaceutical markets related to aging when regulatory approval is received.
- VRT's products will treat ophthalmic conditions that affect large patient populations, creating a substantial market and revenue potential.
- VRT products have demonstrated safety in over 150 patients and exhibit early evidence of efficacy.
- VRT's unique strength has been to carry its product development efforts through early stages, utilizing its network of clinical professionals around the world in the most cost-effective manner. Vitreosolve® is in late stages of development and data from completed studies suggest it to be safe and effective in humans.
- Potential for a strong, proprietary position in the U.S. and abroad.
- Experienced management team with extensive clinical, regulatory, science, manufacturing and entrepreneurial experience, with particular focus on ophthalmic pharmaceuticals.
|
|
|
